Follow your favourite podcasts, listen offline and in the car with CarPlay and Android Auto, and always pick up where you left off. Free to try.
Takeda is entering one of the most pivotal moments in its 245-year history, with a late-stage pipeline poised to transform patient outcomes across three therapeutic areas. Chief Scientific Officer Chris Arendt goes Inside the ICE House to discuss the science behind drug candidates targeting narcolepsy, polycythemia vera, and psoriasis. He explores how AI and computational technologies are reshaping drug discovery and why building the right data foundation is critical to supercharging Takeda's R&D engine.
